To date, no cardiovascular model has been able to shed light on how and why cardiac congenital disorders start in the human embryo. Researchers from the Institute of Molecular Biotechnology (IMBA) in Vienna have been able to recapitulate cardiogenesis in multi-chamber cardioids, sort of interacting heart chambers intended to dissect how genetic and environmental factors impact human heart development.
A Genentech Inc. patent discloses new benzothiazole compounds acting as von Hippel-Lindau disease tumor suppressor (VHL) inhibitors and reported to be useful for the treatment of ischemia, cancer and anemia.
Based on previous studies that have demonstrated the potential of growth hormone-releasing hormone receptor (GHRH-R) antagonists to modulate immune responses to bleomycin lung injury, researchers from the University of Miami and affiliated organizations aimed to evaluate the potential of the GHRH-R antagonist MIA-602 in a mouse model of rVSV-SARS-CoV-2-induced pulmonary dysfunction and heart injury.
4-Hydroxynonenal (4-HNE) is a major byproduct of lipid peroxidation, a process exacerbated by mitochondrial dysfunction and oxidative stress. Accumulation of 4-HNE protein adducts has been reported in several cardiovascular diseases, such as myocardial infarction, hypertension and heart failure in both rodents and humans. Therefore, identifying critical 4-HNE targets relevant to cardiac pathophysiology could help develop better therapies to treat heart failure.
Brise Pharmaceutical (Shanghai) Co. Ltd. has divulged calcitonin gene-related peptide receptor (CALCRL; CGRPR) antagonists reported to be useful for treatment of cerebrovascular and vascular disorders.
Eli Lilly and Co. shared insights into an inhibitor targeting ANGPTL3, named solbinsiran. Solbinsiran, a N-acetylgalactosamine (GalNAc) conjugated Dicer-substrate small interfering RNA (DsiRNA), is designed to target ANGPTL3 expression in the liver.
Bitterroot Bio Inc. presented data on an anti-CD47 hybrid protein, BRB-002, tested in a murine model of atherosclerosis. BRB-002 was tested at 2.5 or 10 mg/kg i.p. 3x/week after a high-fat diet. Firstly, BRB-002 was seen to bind CD47 with high affinity in several cell lines, but not in Jurkat CD47-knockout cells.
The outcomes from two investigational CRISPR-based therapies were presented by researchers from Crispr Therapeutics at the recent American Heart Association’s scientific sessions.
While the human epididymis protein 4 (HE4) has been previously identified as a blood biomarker of fibrosis, the relationship HE4 has with other blood biomarkers has not been established.
The generation of in vitro small blood vessels mimicking the alterations of cerebral small vessel disease (CSVD) allowed a British research group to identify a way to seal leaks to treat conditions such as stroke or vascular dementia. The inhibition of matrix metalloproteinases (MMPs), enzymes that participate in the formation of new vessels, restored the normal union of the cells, preventing the permeability of the system.
RSS
